Evidence map›Paper›PMID 39852534›Full record

ArticleMarine drugs2025

Preclinical Efficacy and Proteomic Prediction of Molecular Targets for s-cal14.1b and s-cal14.2b Conotoxins with Antitumor Capacity in Xenografts of Malignant Pleural Mesothelioma.

Angélica Luna-Nophal, Fernando Díaz-Castillo, Vanessa Izquierdo-Sánchez, Jesús B Velázquez-Fernández, Mario Orozco-Morales, Luis Lara-Mejía, Johana Bernáldez-Sarabia, Noemí Sánchez-Campos, Oscar Arrieta, José Díaz-Chávez and 3 more

Abstract read
In one paragraph

Article in Marine drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Angélica Luna-NophalDoctorado en Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana, Ciudad de Mexico 04960, Mexico.
Fernando Díaz-CastilloDepartamento de Innovación Biomédica, Centro de Investigación Científica y de Educación Superior de Ensenada (CICESE), Ensenada 22860, Mexico.
Vanessa Izquierdo-SánchezLaboratorio de Oncología Experimental, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Ciudad de Mexico 14080, Mexico.ORCID 0000-0003-4839-3504
Jesús B Velázquez-FernándezCONAHCyT-Investigador por Mexico, Ciudad de Mexico 14080, Mexico.
Mario Orozco-MoralesLaboratorio de Oncología Experimental, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Ciudad de Mexico 14080, Mexico.
Luis Lara-MejíaUnidad de Oncología Torácica, Instituto Nacional de Cancerología, Ciudad de Mexico 14080, Mexico.ORCID 0000-0001-8101-4604
Johana Bernáldez-SarabiaDepartamento de Innovación Biomédica, Centro de Investigación Científica y de Educación Superior de Ensenada (CICESE), Ensenada 22860, Mexico.ORCID 0000-0003-4894-5604
Noemí Sánchez-CamposDepartamento de Innovación Biomédica, Centro de Investigación Científica y de Educación Superior de Ensenada (CICESE), Ensenada 22860, Mexico.ORCID 0000-0001-9572-8587
Oscar ArrietaLaboratorio de Oncología Experimental, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Ciudad de Mexico 14080, Mexico.ORCID 0000-0002-1164-3779
José Díaz-ChávezLaboratorio de Oncologia Molecular y Biomarcadores, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Ciudad de Mexico 14080, Mexico.ORCID 0000-0001-9583-3790
Jorge-Ismael Castañeda-SánchezDepartamento de Sistemas Biológicos, Universidad Autónoma Metropolitana, Unidad Xochimilco, Ciudad de Mexico 04960, Mexico.ORCID 0000-0002-4323-4988
Alexei-Fedorovish Licea-NavarroDepartamento de Innovación Biomédica, Centro de Investigación Científica y de Educación Superior de Ensenada (CICESE), Ensenada 22860, Mexico.
Saé Muñiz-HernándezLaboratorio de Oncología Experimental, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Ciudad de Mexico 14080, Mexico.ORCID 0000-0002-6702-4010

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant pleural mesothelioma (MPM) is a rare neoplasm with increasing incidence and mortality rates. Although recent advances have improved the overall prognosis, they have not had an important impact on survival of patients with MPM, such that more effective treatments are needed. Some species of marine snails have been demonstrated to be potential sources of novel anticancer molecules. This study analyzed the anticancer effects in vitro and in vivo of two peptides found in

Indexed as

Antineoplastic AgentsConotoxinsConus SnailLung NeoplasmsMesotheliomaMesothelioma, MalignantPleural NeoplasmsAnimalsApoptosisCell Line, TumorCell ProliferationHumansMiceProteomicsXenograft Model Antitumor AssaysAntineoplastic AgentsConotoxinsmarine toxinsmass spectrometrypharmacological activityprotein markerstherapeutic effect

Identifiers

PMID39852534
PMCPMC11767107

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.